Nektar to Webcast Presentation at Jefferies 2017 London Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Nektar Therapeutics (NKTR) PT Raised to $45 at BTIG Following SITC Meeting
November 13, 2017 8:55 AM ESTBTIG raised its price target on Nektar Therapeutics (NASDAQ: NKTR) to $45.00 (from $35.00) while maintaining a Buy rating. At the Society for Immunotherapy of Cancer meeting (SITC), presentation of oral abstract O20 for NKTR-214, Nektars IL-2-based immune stimulator, was very well received.
NKTR-214 +... More
